## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: Cheng et al.

CASE NO.: CL2029 US NA

**APPLICATION NO.: 10/735,019** 

GROUP ART UNIT: UNKNOWN

FILED: DECEMBER 12, 2003

**EXAMINER: UNKNOWN** 

MUTATIONS AFFECTING PLASMID COPY NUMBER

INFORMATION DISCLOSURE STATEMENT

ssistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In compliance with 37 CFR 1.97 and 1.98, Applicants bring to the attention of the U.S. Patent and Trademark Office information listed on the enclosed PTO/SB/08A and PTO/SB/08B. A copy of the information is also enclosed.

Should any fee be required in connection with the filing of this Information

Disclosure Statement, please charge such fee to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Respectfully submitted

S. NEIL FELTHAM

Attorney for Applicant(s) Registration No. 36,506 Telephone: (302) 992-6460

Facsimile: (302) 892-7949

Dated: 2/12/04

**Enclosures** 

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENT, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THIS DATE.

DATE

MARY BETH PITCHE

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons a

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known				
Filing Date	DECEMBER 12, 2003			
First Named Inventor	CHENG ET AL.			
Group Art Unit	UNKNOWN			
Examiner Name	UNKNOWN			
Attorney Docket Number	CL2029 US NA			

<u> </u>			
# G		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
xaminer Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		Glick, B. R., Pasternak, J.J. Molecular Biotechnology Principles and Applications of Recombinant DNA, 2 <sup>nd</sup> ed. American Society for Microbiology, Washington, D.C. 1998	i
		Grabherr et al., Stabilizing Plasmid Copy Number to Improve Recombinant Protein Produciton, Biotech. Bioeng., Vol. 77: pp. 142-147, 2002	
		Podkovyrov, S.M. and Larson, A new vector-host system for construction of lacZ transcriptional fusions where only low-level gene expression is desirable, T. J., Gene 156: 151-152, 1995	
		Lopilato et al., Mutations in a new chromosomal gene of Escherichia coli K-12, pcnB, reduce plasmid copy number of pBR322 and its derivatives, Mol. Gen. Genet., 205: pp. 285-290, 1986	
		Lui et al., Genetics and Sequence Analysis of the pcnB Locus, and Escherichia coli Gene Involved in Plasmid Copy Number Control, J. Bacteriol., 171: pp. 1254-1261, 1989	
	: .	Wrobel et al., Differential amplification efficiency of pMB1 and p15A (ColE1-type) repllicons in Escherichia coli stringent and relaxed strains starved for particular amino acids, Microbiol. Res., Vol. 152, PP. 251-255, 1997	
		Ederth et al., Origin-specific reduction of ColE1 plasmid copy number due to mutations in a distinct region of the Escherichia coli RNA polymerase, Mol. Gen. Genomics, Vol. 267: 587-592, 2002	
<del></del>			
			<del>                                     </del>

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.